Cargando…

Cell-cycle coupled expansion of AR activity promotes cancer progression

The androgen receptor (AR) is required for prostate cancer (PCa) survival and progression, and ablation of AR activity is the first line of therapeutic intervention for disseminated disease. While initially effective, recurrent tumors ultimately arise for which there is no durable cure. Despite the...

Descripción completa

Detalles Bibliográficos
Autores principales:	McNair, Christopher, Urbanucci, Alfonso, Comstock, Clay E.S., Augello, Michael A., Goodwin, Jonathan F., Launchbury, Rosalind, Zhao, Shuang, Schiewer, Mathew J., Ertel, Adam, Karnes, Jeffrey, Davicioni, Elai, Wang, Liguo, Wang, Qianben, Mills, Ian G., Feng, Felix Y., Li, Wei, Carroll, Jason S., Knudsen, Karen E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364060/ https://www.ncbi.nlm.nih.gov/pubmed/27669432 http://dx.doi.org/10.1038/onc.2016.334

Ejemplares similares

Prostate cancer in young men represents a distinct clinical phenotype: gene expression signature to predict early metastases
por: Ding, Yuan C., et al.
Publicado: (2021)

mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer
por: Schiewer, Matthew J, et al.
Publicado: (2012)

Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
por: Handle, Florian, et al.
Publicado: (2019)

G3BP1 inhibits Cul3(SPOP) to amplify AR signaling and promote prostate cancer
por: Mukhopadhyay, Chandrani, et al.
Publicado: (2021)

A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
por: He, Yundong, et al.
Publicado: (2021)

Evolving transcriptomic fingerprint based on genome‐wide data as prognostic tools in prostate cancer
por: Alshalalfa, Mohammed, et al.
Publicado: (2015)

AMPed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy
por: Schiewer, Matthew J, et al.
Publicado: (2014)

AR, the cell cycle, and prostate cancer
por: Balk, Steven P., et al.
Publicado: (2008)

Transcriptome-Wide Detection of Differentially Expressed Coding and Non-Coding Transcripts and Their Clinical Significance in Prostate Cancer
por: Erho, Nicholas, et al.
Publicado: (2012)

Unexpected frequency of the pathogenic AR CAG repeat expansion in the general population
por: Zanovello, Matteo, et al.
Publicado: (2023)

A comparative study of PCS and PAM50 prostate cancer classification schemes
por: Yoon, Junhee, et al.
Publicado: (2021)

Targeting cell cycle and hormone receptor pathways in cancer
por: Comstock, C E S, et al.
Publicado: (2013)

Inferring cancer subnetwork markers using density-constrained biclustering
por: Dao, Phuong, et al.
Publicado: (2010)

Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma
por: Tsai, Harrison K., et al.
Publicado: (2017)

Mutant p53 elicits context-dependent pro-tumorigenic phenotypes
por: McCann, Jennifer J., et al.
Publicado: (2021)

High OGT activity is essential for MYC-driven proliferation of prostate cancer cells
por: Itkonen, Harri M, et al.
Publicado: (2019)

Development of a predictive model for stromal content in prostate cancer samples to improve signature performance
por: Boufaied, Nadia, et al.
Publicado: (2019)

Prostate Cancer Tumor Volume and Genomic Risk
por: Ramaswamy, Ashwin, et al.
Publicado: (2023)

$^{43}$Ar and $^{44}$Ar
por: Hudis, J, et al.
Publicado: (1970)

$^{43}Ar$ and $^{44}Ar$
por: Hudis, J, et al.
Publicado: (1970)

To Be(Ar) Or Not to Be(Ar) – Jones Dilemma?
por: Andrews, Nicholas A., et al.
Publicado: (2022)

Lipid degradation promotes prostate cancer cell survival
por: Itkonen, Harri M, et al.
Publicado: (2017)

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer
por: Gordon, Nicolas, et al.
Publicado: (2023)

Unique Bisphenol A Transcriptome in Prostate Cancer: Novel Effects on ERβ Expression That Correspond to Androgen Receptor Mutation Status
por: Hess-Wilson, Janet K., et al.
Publicado: (2007)

Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1
por: Spans, Lien, et al.
Publicado: (2016)

Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer
por: Mandigo, Amy C., et al.
Publicado: (2022)

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
por: Wüstmann, Neele, et al.
Publicado: (2023)

Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer
por: Feng, Ye, et al.
Publicado: (2019)

Dual inhibition of AKT‐mTOR and AR signaling by targeting HDAC3 in PTEN‐ or SPOP‐mutated prostate cancer
por: Yan, Yuqian, et al.
Publicado: (2018)

On atmospheric $^{39}Ar$ and $^{42}Ar$ abundance
por: Cennini, P, et al.
Publicado: (1995)

Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity
por: Grbesa, Ivana, et al.
Publicado: (2021)

Multiple ionization of He, Ne, and Ar by fast protons and antiprotons
por: Andersen, L H, et al.
Publicado: (1987)

Ár njöt'i ar hai = El color de la tierra
Publicado: (2014)

The mass of $^{32}Ar$ and $^{33}Ar$ for fundamental tests
por: Blaum, K, et al.
Publicado: (2003)

Masses of 32Ar and 33Ar for fundamental tests
por: Blaum, K, et al.
Publicado: (2003)

AR Splicing Variants and Resistance to AR Targeting Agents
por: Kanayama, Mayuko, et al.
Publicado: (2021)

The HACMS program: using formal methods to eliminate exploitable bugs
por: Fisher, Kathleen, et al.
Publicado: (2017)

Genomic “Dark Matter” in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers
por: Vergara, Ismael A., et al.
Publicado: (2012)

Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group
por: Badani, Ketan, et al.
Publicado: (2013)

Determination of $^{44}Ar$(n,$\gamma$)$^{45}$Ar, and $^{46}$Ar(n,$\gamma$)$^{47}$Ar reaction rates by (d,p) transfer reactions
por: Sorlin, O, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_1rouchtreegn5laetonfn88lcc